UHPLC Analysis of Reduced IgG1 on BIOshell[™] IgG 1000 Å C18



Supelco



Conditions:

column:	BIOshell™ IgG 1000 Å C18, 15 cm x 2.1 mm I.D., 2.7 µm
mobile phase:	[A] Water (0.1% v/v TFA); [B] Acetonitrile (0.1% v/v TFA)
gradient:	30% B to 40% B in 14.0 min
flow rate:	0.4 mL/min
column temp.:	80 °C
detector:	UV 280 nm, PDA
injection:	2 μL
sample:	reduced Trastuzumab, 400 µg/mL, water with 1.2M Guanidine/0.1% TFA

Description:

The 2.7 µm BIOshell[™] IgG 1000 Å C18 is ideal for analysis of monoclonal antibodies such as trastuzumab. Trastuzumab is a monoclonal antibody that is used primarily to treat breast cancer, but can also be used in the treatment of stomach and esophageal cancers. 2 mg/mL trastuzumab was incubated at 60 °C for 1 hour using 20 mM DTT, 6 M Guanidine, and 50 mM Tris pH 7.8. This separation of the light and heavy chains is useful for quantification and analysis.

Materials:

Product Part Number	Description
270733	Water
34851	Acetonitrile
302031	TFA
582703-U	BIOshell™IgG 1000 Å C18 2.7 µm 15 cm x 2.1 mm

The life science business of Merck KGaA, Darmstadt, Germany operates as MilliporeSigma in the U.S. and Canada.

SigmaAldrich.com

© 2018 Merck KGaA, Darnstadt, Germany and/or its affiliates. All Rights Reserved. MilliporeSigma, Supeko, and the vibrant M are trademarks of Merck KGaA, Darnstadt, Germany or Its affiliates. All other trademarks are the property of their respective owners. Detailed information on trademarks is available in publicly accessible resources. Ltr. No. 47000000000 X000